What’s Better for Weight Loss: Wegovy or Mounjaro?

Last reviewed: June 19, 2026

Last updated: June 19, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide (Wegovy) and tirzepatide (Mounjaro) are both FDA-approved GLP-1 medications, but they work through different mechanisms in your body. Clinical trials show tirzepatide produces greater average weight loss—up to 22% of body weight over 68 weeks—compared to semaglutide's 16-18% reduction. PlexusDx provides compounded versions of both, personalized to your genetic peptide pathways.

How Semaglutide and Tirzepatide Work Differently

Semaglutide (Wegovy) activates only the GLP-1 receptor, which signals your brain that you're full, slows stomach emptying, and reduces appetite hormones. This single-target approach has been effective for millions of patients since its approval. However, it leaves other metabolic pathways untouched.

Tirzepatide (Mounjaro) acts as a dual GLP-1 and GIP receptor agonist, meaning it activates two separate appetite and metabolism control systems simultaneously. The GIP pathway manages glucose regulation and fat storage differently than GLP-1 alone. This dual activation may explain why tirzepatide shows stronger weight loss results in head-to-head comparisons.

Clinical Evidence: Which Produces Better Weight Loss?

The SURMOUNT trials demonstrated that tirzepatide at its highest dose led to approximately 22.5% body weight reduction, while comparable semaglutide dosing achieved around 17% reduction over the same timeframe. Both medications significantly improved blood sugar control, blood pressure, and cardiovascular markers. The difference represents meaningful clinical advantage for patients seeking maximum weight loss impact.

Individual response varies considerably based on genetics, metabolism, and lifestyle factors. Some patients respond excellently to semaglutide alone, while others need tirzepatide's dual mechanism to reach their goals. PlexusDx's Precision Peptide Genetic Test analyzes your GLP1R and GIPR variants to predict which pathway strength matters most for your body.

Cost Comparison and Accessibility of Both Medications

Brand-name Wegovy typically costs $900-$1,300 monthly without insurance, while brand Mounjaro ranges from $900-$1,600 depending on dose and pharmacy. Neither price reflects what most patients actually pay out-of-pocket. Insurance coverage is unpredictable and often requires prior authorization, waiting periods, or step-therapy protocols.

PlexusDx compounded tirzepatide injection starts at $249 per month with no insurance required, no membership fees, and HSA/FSA eligibility. Compounded semaglutide begins at $149/month. Both work through your body the same way as brand versions but come from licensed 503A compounding pharmacies. Your dose may need to go up as your body adjusts, but your price won't increase—flat pricing across all commitment tiers.

Personalization: Why Your Genetic Profile Matters

Not every patient benefits equally from semaglutide or tirzepatide because genetic variation in the GLP1R and GIPR genes affects how strongly these medications activate your appetite and metabolism centers. A patient with a less responsive GLP1R variant might need tirzepatide's dual action to achieve weight loss, while another with strong GLP1R signaling might do well on semaglutide alone. This explains why some people experience rapid success while others plateau.

PlexusDx's Precision Peptide Genetic Test ($99 after your first month of treatment) maps 14 metabolic pathways and 49 peptides, including critical variants like GIPR rs1800437 and GLP1R rs6923761. This insight guides your prescriber toward the compound, dose, and therapy combination most likely to work with your unique genetic architecture. Personalization removes guesswork and optimizes your investment in weight loss therapy.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Which medication will help me lose more weight—Wegovy or Mounjaro?

Clinical trials show tirzepatide (Mounjaro's active ingredient) produces approximately 5-6% greater body weight loss than semaglutide on average. However, individual results depend on your genetics, adherence, and lifestyle. PlexusDx compounded tirzepatide injection starts at $249/month and includes genetic testing access to predict your likely response.

What's the difference between Wegovy and compounded semaglutide?

Wegovy and PlexusDx compounded semaglutide contain identical active pharmaceutical ingredients manufactured by the same processes. The difference is sourcing: Wegovy comes from Novo Nordisk's manufacturing, while PlexusDx sources from licensed 503A compounding pharmacies. Compounded versions cost significantly less ($149/mo vs. $900+) and require no insurance.

Why is compounded tirzepatide cheaper than brand Mounjaro?

Brand Mounjaro carries manufacturing, distribution, marketing, and profit-margin costs that licensed 503A compounding pharmacies avoid. PlexusDx compounded tirzepatide injection starts at $249/month because it's prepared by certified compounders without brand-level overhead. All medications are sterile, potent, and tested for quality.

Are there serious side effects with either semaglutide or tirzepatide?

Both medications can cause nausea, vomiting, and diarrhea, especially at dose initiation—typically mild and temporary. Rare serious risks include pancreatitis, gallbladder issues, and thyroid concerns; discuss personal or family thyroid history with your provider. Most patients tolerate these medications well when dosed gradually, which PlexusDx's titration protocols support.

How does the Precision Peptide Genetic Test help me choose between medications?

The test analyzes your GLP1R, GIPR, FTO, and MC4R genetic variants to show which peptide pathways are most active in your metabolism. If your GLP1R is strong but GIPR is weaker, semaglutide alone may work well. If both are moderate, tirzepatide's dual action offers better coverage. This personalization increases your likelihood of success and helps avoid ineffective trial-and-error dosing.

Related Reading

• Wegovy For Weight Loss 2
• Mounjaro For Weight Loss 2
• Wegovy Weight Loss Pills
• Weight Loss Mounjaro

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.